CRSP Key Statistics, Chart & Performance
The current stock price of CRSP is 53.84 USD. In the past month the price decreased by -6.51%. In the past year, price increased by 35.65%.
CRSP Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.29 | 388.96B | ||
| AMGN | AMGEN INC | 14.91 | 175.60B | ||
| GILD | GILEAD SCIENCES INC | 14.79 | 150.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.72 | 117.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.7 | 83.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 780.96 | 52.62B | ||
| INSM | INSMED INC | N/A | 37.53B | ||
| NTRA | NATERA INC | N/A | 32.34B | ||
| BIIB | BIOGEN INC | 11.21 | 27.52B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.31 | 20.81B | ||
| INCY | INCYTE CORP | 16.65 | 20.98B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.94B |
Related stock screener links
About CRSP
Company Profile
CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. The company is headquartered in Zug, Zug and currently employs 393 full-time employees. The company went IPO on 2016-10-19. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The firm aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The firm has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The firm product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.
Company Info
CRISPR THERAPEUTICS AG
Baarerstrasse 14
Zug ZUG CH-6300 CH
CEO: Samarth Kulkarni
Employees: 393
Phone: 41415613279
CRISPR THERAPEUTICS AG / CRSP FAQ
Can you describe the business of CRISPR THERAPEUTICS AG?
CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. The company is headquartered in Zug, Zug and currently employs 393 full-time employees. The company went IPO on 2016-10-19. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The firm aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The firm has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The firm product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.
What is the current price of CRSP stock?
The current stock price of CRSP is 53.84 USD. The price decreased by -4.54% in the last trading session.
Does CRSP stock pay dividends?
CRSP does not pay a dividend.
How is the ChartMill rating for CRISPR THERAPEUTICS AG?
CRSP has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Is CRISPR THERAPEUTICS AG (CRSP) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on CRSP.
Can you provide the number of employees for CRISPR THERAPEUTICS AG?
CRISPR THERAPEUTICS AG (CRSP) currently has 393 employees.
What is the market capitalization of CRSP stock?
CRISPR THERAPEUTICS AG (CRSP) has a market capitalization of 5.13B USD. This makes CRSP a Mid Cap stock.
CRSP Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to CRSP. When comparing the yearly performance of all stocks, CRSP turns out to be only a medium performer in the overall market: it outperformed 49.65% of all stocks.
CRSP Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CRSP. No worries on liquidiy or solvency for CRSP as it has an excellent financial health rating, but there are worries on the profitability.
CRSP Financial Highlights
Over the last trailing twelve months CRSP reported a non-GAAP Earnings per Share(EPS) of -4.48. The EPS decreased by -58.3% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -21.75% | ||
| ROE | -25.49% | ||
| Debt/Equity | 0 |
CRSP Forecast & Estimates
36 analysts have analysed CRSP and the average price target is 80.19 USD. This implies a price increase of 48.95% is expected in the next year compared to the current price of 53.84.
For the next year, analysts expect an EPS growth of -44.72% and a revenue growth 1.98% for CRSP